Compare SNGX & YDKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | YDKG |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | United States | China |
| Employees | N/A | 17 |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 4.8M |
| IPO Year | 2006 | N/A |
| Metric | SNGX | YDKG |
|---|---|---|
| Price | $0.37 | $0.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 608.4K | 86.2K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,371.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.02 |
| 52 Week High | $6.23 | $3.90 |
| Indicator | SNGX | YDKG |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 60.18 |
| Support Level | $0.28 | $0.81 |
| Resistance Level | $0.41 | $1.04 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 15.68 | 100.00 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.